Compounds of the formula ##STR1## wherein L, M, R, T and X are set forth in the description, as well as hydrates or solvates thereof, which inhibit thrombin-induced platelet aggregation and clotting of fibrinogen in plasma, are described. The compounds of formula I are prepared by amidination or, depending on whether L is NH or O, by amide formation or esterification.
Dipeptide p-amidinobenzylamides with N-terminal sulfonyl or
申请人:BASF Aktiengesellschaft
公开号:US05852051A1
公开(公告)日:1998-12-22
Compounds of the formula I ##STR1## in which R.sup.1, A and B have the meanings stated in the description, and the preparation thereof are described. The novel compounds are suitable for controlling diseases.
[DE] NEUE DIPEPTIDISCHE P-AMIDINOBENZYLAMIDE MIT N-TERMINALEN SULFONYL- BZW. AMINOSULFONYLRESTEN<br/>[EN] NEW DIPEPTIDE P-AMIDINOBENZYLAMIDES WITH N-TERMINAL SULFONYL OR AMINOSULFONYL RADICALS<br/>[FR] NOUVEAUX P-AMIDINOBENZYLAMIDES DIPEPTIDIQUES A RESTES N-TERMINAUX SULFONYLE OU AMINOSULFONYLE
申请人:BASF AKTIENGESELLSCHAFT
公开号:WO1996017860A1
公开(公告)日:1996-06-13
(DE) Es werden Verbindungen der Formel (I), worin R1, A und B die in der Beschreibung angegebene Bedeutung besitzen, sowie deren Herstellung beschrieben. Die neuen Verbindungen eignen sich zur Bekämpfung von Krankheiten.(EN) The invention pertains to compounds of formula (I), wherein R1, A and B are as indicated in the description, and to their preparation. The new compounds can be used for combatting diseases.(FR) L'invention concerne des composés de formule (I), dans laquelle R1, A et B ont les notations données dans la description, ainsi que leur fabrication. Ces nouveaux composés sont utiles pour combattre des maladies.
Design and Synthesis of Potent and Highly Selective Thrombin Inhibitors
作者:Kurt Hilpert、Jean Ackermann、David W. Banner、Alain Gast、Klaus Gubernator、Paul Hadvary、Ludvik Labler、Klaus Mueller、Gerard Schmid、Thomas B. Tschopp、Han van de Waterbeemd
DOI:10.1021/jm00049a008
日期:1994.11.1
Thrombin, a serine protease, plays a central role in the initiation and propagation of thrombotic events. An extensive search for new thrombin inhibitors was performed, using an unconventional approach. Screening of small basic molecules for binding in the recognition pocket of thrombin led to the discovery of (aminoiminomethyl)piperidine (amidinopiperidine) as a weak, but intrinsically selective, thrombin inhibitor. Elaboration of this molecule provided compounds which inhibit thrombin with K-i's in the range of 20-50 nM and with selectivities of 1000-4000 against trypsin. These inhibitor compounds show a new and unexpected, binding mode to thrombin. Modification of the central building block and then of one of the hydrophobic substituents led to the discovery of a new family of thrombin inhibitors which has reverted td the former binding mode to thrombin. This last class of compounds shows inhibitory activities in the picomolar range; low toxicity; and a short plasma half life which favors its use for an intravenous application. From this series of thrombin;inhibitors, 19f (Ro 46-6240) was selected for clinical development as an antithrombotic agent for intravenous administration.